flow trial semaglutide kidney 2024 Effects of Once-Weekly on Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 FLOW Study Highlights: How Semaglutide
Description
Semaglutide reduces appetite through direct effects on hypothalamic appetite centers, decreased hunger hormone ghrelin levels, and enhanced satiety signaling
the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial substantiates this effect [31,32]
Thinking about stopping it
Combining these advancements with other treatment modalities may further optimize their potential, creating a more comprehensive framework for managing T2DM and related metabolic disorders
